In December, SQZ partnered with global pharma firm and cancer treatment leader F. Hoffmann - La Roche in a deal that could be worth $ 500 million or more — a large
undisclosed upfront payment, and additional sums when SQZ meets certain milestones — to speed up the development of its technology specifically to inject a person's immune cells with a protein to activate a «killer T» cell response to fight off cancer.